SG Americas Securities LLC Grows Position in Annexon, Inc. (NASDAQ:ANNX)

SG Americas Securities LLC lifted its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 14.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,335 shares of the company’s stock after buying an additional 3,123 shares during the period. SG Americas Securities LLC’s holdings in Annexon were worth $115,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Quantbot Technologies LP boosted its position in shares of Annexon by 630.8% during the first quarter. Quantbot Technologies LP now owns 9,500 shares of the company’s stock valued at $25,000 after buying an additional 8,200 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Annexon by 31.3% during the first quarter. Tower Research Capital LLC TRC now owns 7,992 shares of the company’s stock valued at $31,000 after buying an additional 1,903 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Annexon during the first quarter valued at $41,000. Hsbc Holdings PLC purchased a new stake in shares of Annexon during the third quarter valued at $45,000. Finally, Jane Street Group LLC purchased a new stake in shares of Annexon during the first quarter valued at $46,000.

Annexon Stock Performance

Shares of Annexon stock opened at $4.44 on Friday. The stock has a market cap of $399.73 million, a price-to-earnings ratio of -2.49 and a beta of 1.14. The stock has a 50 day moving average price of $5.77 and a 200-day moving average price of $4.04. Annexon, Inc. has a one year low of $1.57 and a one year high of $8.40.

Annexon (NASDAQ:ANNX) last announced its earnings results on Tuesday, March 26th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. Sell-side analysts predict that Annexon, Inc. will post -1.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANNX has been the topic of several research reports. Bank of America raised their target price on Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Thursday, April 11th. Wells Fargo & Company raised their target price on Annexon from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Annexon in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. raised their target price on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, April 1st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Annexon currently has a consensus rating of “Buy” and a consensus target price of $14.43.

Insider Activity at Annexon

In related news, CEO Douglas Love sold 5,782 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $5.54, for a total transaction of $32,032.28. Following the completion of the transaction, the chief executive officer now owns 196,121 shares in the company, valued at approximately $1,086,510.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 8,940 shares of company stock worth $49,514 in the last quarter. 19.11% of the stock is owned by company insiders.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.